HUTCHMED Ltd (HCM) Form 6-K — Aug 17, 2026
HUTCHMED announced that its global SAFFRON Phase III trial showed ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) delivered a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival versus doublet platinum chemotherapy in MET-driven EGFR-mutated non-small cell lung cancer after progression on TAGRISSO. It is the first global Phase III trial to show significant PFS and OS benefits in this setting. The trial enrolled 338 patients across 230 centers in 29 countries, and the safety profile was consistent with the known profiles of each medicine with no new safety findings.
Key figures
- Orpathys dose
- 300mg twice daily
- Tagrisso dose
- 80mg once daily
- Saffron centers
- 230
- Saffron patients
- 338
- Saffron countries
- 29
- Met resistance incidence
- approximately 34% of tumors develop high MET overexpression or amplification after progression on a third-generation EGFR TKI
- Tagrisso patients treated
- more than one million patients worldwide
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.